2026-07-23T23:01:35Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/230962024-11-29T23:54:16Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597
Repisalud
author
Horgan, Denis
author
Van den Bulcke, Marc
author
Malapelle, Umberto
author
Troncone, Giancarlo
author
Normanno, Nicola
author
Capoluongo, Ettore D
author
Prelaj, Arsela
author
Rizzari, Carmelo
author
Trapani, Dario
author
Singh, Jaya
author
Kozaric, Marta
author
Longshore, John
author
Ottaviano, Manuel
author
Boccia, Stefania
author
Pravettoni, Gabriella
author
Cattaneo, Ivana
author
Malats, Nuria
author
Buettner, Reinhard
author
Lekadir, Karim
author
de Lorenzo, Francesco
author
Hofman, Paul
author
De Maria, Ruggero
2024-09-16T08:17:01Z
2024-09-16T08:17:01Z
2024-01-15
Heliyon . 2023 ;10(1):e23914
10.1016/j.heliyon.2023.e23914
2405-8440
Heliyon
38234913
https://hdl.handle.net/20.500.12105/23096
Next-generation sequencing (NGS) and liquid biopsy (LB) showed positive results in the fight against different cancer types. This paper aims to assess the uptake of advanced molecular diagnostics/NGS for quick and efficient genetic profiles of tumour cells. For that purpose, the European Alliance for Personalised Medicine conducted a series of expert interviews to ascertain the current status across member states. One stakeholder meeting was additionally conducted to prioritize relevant factors by stakeholders. Seven common pillars were identified, and twenty-five measures were defined based on these pillars. Results showed that a multi-faceted approach is necessary for successful NGS implementation and that regional differences may be influenced by healthcare policies, resources, and infrastructure. It is important to consider different correlations when interpreting the results and to use them as a starting point for further discussion.
eng
Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems.
research article